pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
552
stories
22d
Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
fiercebiotech
22d
Unlocking cell surface protein research with site-specific labeling
biospace
23d
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
24d
Akeso details survival win for its PD-1xVEGF drug versus Keytruda
endpoints
25d
Disc sets up polycythemia vera challenge but Silence maintains lead
biospace
25d
Novartis drags peers down with triple asset stumble
biospace
25d
Novartis drags peers down with triple asset failure
biospace
25d
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
fiercebiotech
25d
GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck
fiercebiotech
26d
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
biospace
26d
Takeda’s long-term R&D head announces exit after major pipeline reorganization
biospace
26d
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
26d
Novartis shareholder calls for board overhaul following costly deal setbacks: Reuters
fiercebiotech
27d
CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
fiercebiotech
27d
Solstice rises with $225M to develop next-gen CTLA-4 drug from China
biospace
27d
Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic
endpoints
27d
A new immuno-oncology play raises $225M for a next-generation drug
biopharma dive
28d
Beyond China: Five other overseas destinations for biopharma dollars
biospace
28d
Steady stream of crossover rounds stock biotech's IPO pipeline
biospace
28d
Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2
fiercebiotech
28d
Novartis’ $12B Avidity acquisition hits Phase 3 speedbump as dystrophy drug disappoints
biospace
28d
BrainChild Bio targets deadly pediatric brain cancer with $116M series A
biospace
28d
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
fiercebiotech
28d
Spyre's 3-pronged IBD strategy on track as IL-23 antibody rounds off trio of phase 2 wins
fiercebiotech
28d
Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint
fiercebiotech
29d
4 CDMOs to consider when outsourcing manufacturing
biospace
29d
Reeling from past failures, Parkinson's pipeline enters 'era of diversification'
biospace
29d
Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
fiercebiotech
29d
Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durability
fiercebiotech
29d
Novo’s blockbuster hopes for CKD program dwindle after more phase 3 trials scrapped
fiercebiotech
← prev
page 5 of 19
next →
